Therapeutic Targets Database
BIDD Pharmainformatics Databases


TTD Drug ID: DAP000736

Drug Information
SynonymsHMS2090P19; KBio1_000252; NCGC00016889-01; 3-[hydroxy-(pyridin-2-ylamino)methylidene]-2-methyl-1,1-dioxothieno[2,3-e]thiazin-4-one; SMR000058865; Tenoxicamum [INN-Latin]; CID5312154; C032801; AKOS000282084; Solvay brand of tenoxicam; Bio-0104; MLS001074071; CCRIS 5264; BCBcMAP01_000251; CID5282194; CID5397; S2512_Selleck; Tilcotil; Spectrum_001430; HMS2092L20; KBio2_004478; Spectrum2_001080; HMS1569J15; AC-4526; (3Z)-3-[hydroxy-(pyridin-2-ylamino)methylidene]-2-methyl-1,1-dioxothieno[2,3-e]thiazin-4-one; Liman; KBio2_007046; DivK1c_000252; Ro 12-0068; KBioSS_001910; BRN 0572193; STK637103; Prestwick2_000527; Ro-120068; HMS500M14; Spectrum5_001615; Ambap59804-37-4; Tilcotil (TN); D01767; NCGC00095260-01; Tenoxicam [USAN:BAN:INN:JAN]; LS-152556; Roche brand of tenoxicam; Prestwick1_000527; Prestwick_849; Novag brand of tenoxicam; Prestwick3_000527; Spectrum3_001563; Mobiflex; Apotex brand of tenoxicam; SMP1_000040; KBioGR_001022; Novo-Tenoxicam; 4-Hydroxy-2-methyl-N-2-pyridinyl-2H-thieno(2,3-e)-1,2-thiazine-3-carboxamide 1,1-dioxide; 4-HYDROXY-2-METHYL-N-2-PYRIDINYL-2H-THIENO[2,3-E]-1,2-THIAZINE-3-CARBOXAMIDE 1,1-DIOXIDE; MLS000069830; Spectrum4_000731; Ro 12-0068/000; SPBio_001100; UNII-Z1R9N0A399; SPBio_002434; (3E)-3-[hydroxy-(pyridin-2-ylamino)methylidene]-2-methyl-1,1-dioxothieno[2,3-e]thiazin-4-one; BSPBio_000513; tenoxicam; CHEMBL487234; T0909_SIGMA; IDI1_000252; 59804-37-4; CAS-59804-37-4; BSPBio_003066; 4-hydroxy-2-methyl-N-(pyridin-2-yl)-2H-thieno[2,3-e][1,2]thiazine-3-carboxamide 1,1-dioxide; BPBio1_000565; KBio3_002566; 2H-Thieno(2,3-e)-1,2-thiazine-3-carboxamide, 4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide; Artriunic; HMS1923I15; AC1NQZN7; NINDS_000252; MolPort-000-884-690; DB00469; Novopharm brand of tenoxicam; 4-Hydroxy-2-methyl-N-2-pyridyl-2H-thieno(2,3-e)-1,2-thiazine-3-carboxamide 1,1-dioxide; SPECTRUM1503142; AC1NSM4C; Tenoxicam (JAN/USAN/INN); AC1L1K9K; Prestwick0_000527; KBio2_001910; Tenoxicamum; I02-0320; BIDD:GT0650; NCGC00095260-02; Reutenox; Apo-Tenoxicam; Ro-12-0068    
Trade NameMobiflex    
CompanyRoche Laboratories Inc    
IndicationRheumatoid arthritis and osteoarthritisApproved    [1]

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
Therapeutic ClassAnti-Inflammatory Agents    
CAS NumberCAS 59804-37-4
PubChem Compound IDCID 5397.    
PubChem Substance IDSID 5639774.    
SuperDrug ATC IDM01AC02;    
SuperDrug CAS ID059804374;    
TargetProstaglandin G/H synthase 2Inhibitor[2][3]
Ref 1Drug information of Tenoxicam, 2008 To Reference
Ref 2The use and safety profile of non-steroidal antiinflammatory drugs among Turkish patients with osteoarthritis. Turk J Gastroenterol. 2005 Sep;16(3):138-42. To Reference
Ref 3A randomized crossover trial of tenoxicam compared with rofecoxib for postoperative dental pain control. Anaesth Intensive Care. 2004 Dec;32(6):770-4. To Reference


Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.

Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore

All rights reserved.

Computer-aided Drug Design
About BIDD | Databases | Software | Teaching | Research |  Links

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543